Sanoculis

Company Overview

Snapshot

Founded in February 2012 by Nir Israeli, Vadim Shmukler, and Dr. Yoseph Glovinsky, Sanoculis operates with 1-10 employees. The company has raised $18.5 million across 3 funding rounds from 6 investors. In April 2025, Sanoculis received CE Mark approval for its MINT® product, a stent-free technology platform for glaucoma angle surgery.

Business overview

Sanoculis is a Health Tech & Life Sciences company specializing in ophthalmic medical devices for glaucoma treatment. The company's core technology, Minimally Invasive Micro Sclerostomy (MIMS), and its MINT® product, offer a less invasive surgical procedure to reduce intraocular pressure. Sanoculis serves the healthcare industry, targeting hospitals, surgeons, and clinics with its medical treatment and therapeutics solutions for eye diseases.

Strategic signal

In April 2025, Sanoculis received CE Mark approval under the Medical Device Regulation (MDR) in the EU for its MINT® product. This approval is a significant milestone, validating the company's stent-free technology platform for glaucoma angle surgery and enabling a selective commercial pre-launch rollout. This signals strong market readiness and potential for increased adoption of its innovative glaucoma treatment solutions.

Company Intelligence Q&A

What is the most recent regulatory approval Sanoculis has received?

In April 2025, Sanoculis received CE Mark approval under the Medical Device Regulation (MDR) in the EU for its MINT® product, a stent-free technology platform for glaucoma angle surgery.

Which companies invested in Sanoculis's Series C funding round and entered into strategic agreements?

In July 2022, Bausch + Lomb and Eckuity invested in Sanoculis as part of a Series C funding round. Bausch + Lomb also entered into an exclusive European distribution agreement for Sanoculis's MIMS® device and an option agreement to purchase all of Sanoculis's assets.

What is the primary product developed by Sanoculis?

Sanoculis develops the Minimally Invasive Micro Sclerostomy (MIMS) solution, which consists of a single-patient-use sterile tool and a multi-use external machine designed to create a sclero-corneal drainage channel to reduce intraocular pressure for glaucoma treatment.

When did Sanoculis receive its initial CE marking for the MIMS device?

In March 2017, Sanoculis was granted CE marking for its MIMS device and procedure.

What was the focus of the Series B funding round in September 2019?

In September 2019, Sanoculis secured a Series B funding round with investments from HCS Capital and BIOLIGHT Life Sciences.